MedTrace Logo

Comparing the Efficiency of Three Third-generation Supraglottic Airways as an Intubation Route

NCT02975466 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2018-05-09

No results posted yet for this study

Summary

A "can't intubate, can't oxygenate" situation is life-threatening and the physician must be prepared to react quickly. Similarly, a difficult intubation with adequate ventilation is associated with complications. In both of these situation and as recommend by different societies, a supra-glottic airway (SGA) device can be used to help ventilation, or as an intubation conduit to ease the airway access. The objective of this randomized controlled trial is to establish which SGA, between the AuraGain, AirQ Blocker and I-Gel, allows the fastest intubation time in an adult population, with the objective of minimizing complications related to these situations. The investigators will conduct a three-arm trial to compare different outcomes related to the installation of the SGA and its use as an intubation conduit. The results of this trial will inform the anesthesiologist on which device to use on to have close in case of airway emergencies.

Conditions

  • Difficult Intubation

Interventions

DEVICE

Insertion of AirQ Blocker and intubation through the device

Insertion of the SGA device and evaluation of easiness of endotracheal intubation

DEVICE

Insertion of AuraGain and intubation through the device

Insertion of the SGA device and evaluation of easiness of endotracheal intubation

DEVICE

Insertion of I-Gel and intubation through the device

Insertion of the SGA device and evaluation of easiness of endotracheal intubation

Sponsors & Collaborators

  • Université de Sherbrooke

    lead OTHER

Principal Investigators

  • Marie-José Colas, MD · Centre Hospitalier Universitaire de Sherbrooke (CHUS)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-03-21
Primary Completion
2018-01-01
Completion
2018-01-01

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02975466 on ClinicalTrials.gov